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Hormone replacement therapy (HRT) is used by an increasing
number of women to relieve menopausal problems. A protective
effect against bone loss and cardiovascular disease has been
demonstrated. One study has reported that oestrogen replacement
therapy prolonged survival in women when coronary artery
disease was present, whereas less effect was seen in absence of
coronary artery disease (Sullivan et al, 1990). However, in a
randomized placebo controlled trial of HRT in women with coro-
nary heart disease, there was no significant difference between
groups in occurrence of non-fatal myocardial infarction or coro-
nary heart disease (Hulley et al, 1998). Concern has been raised
about an increased incidence of breast cancer after HRT use,
especially after more than 10 years of use (Grodstein et al, 1997).
In the collaborative re-analysis of 51 studies the breast cancer risk
was found to be increased by 2.3% per year of use and to be
greatest during and shortly after discontinuation of HRT
(Collaborative Group on Hormonal Factors in Breast Cancer,
1997). In general, no increased mortality due to breast cancer in
women who have used HRT has been shown (Hunt et al, 1990;
Henderson et al, 1991; Yuen et al, 1993; Willis et al, 1996).
However, concern has been raised after long-term (>10 years) use
(Grodstein et al, 1997). Less advanced clinical stage at breast
cancer diagnosis among HRT users has been reported by three
studies and may account for the decreased mortality rate in some
studies (Brinton et al, 1986; Bergkvist et al, 1989; Magnusson
et al, 1996). The less advanced clinical stage may be due to
surveillance bias (Schairer et al, 1994), a healthy oestrogen user
bias (Yuen et al, 1993), selection bias (Henderson et al, 1991), or a
modifying effect from HRT on the tumour biology (Squitieri et al,
1994; Bonnier et al, 1995; Salmon et al, 1995; Harding et al, 1996;
Magnusson et al, 1996).
In observational studies, HRT has been shown to reduce the risk
of cardiovascular disease; this was, however, not confirmed in a
randomized placebo controlled trial (Hulley et al, 1998). Other
positive effects such as decreased risk of osteoporosis, while nega-
tive effects such as an increased risk of breast cancer have also
been demonstrated (Collaborative Group on Hormonal Factors in
Breast Cancer, 1997). We have studied the total effect on survival
in 984 women with breast cancer, comparing women who ever
used HRT before diagnosis with never users in relation to overall
survival. Tumour oestrogen receptor (ER) and progesterone
receptor (PR) status, tumour stage and the mode of diagnosis have
also been investigated and related to ever-use of HRT before
diagnosis and overall survival.
MATERIALS AND METHODS
Approximately 25–33% of all breast cancer patients from the
south Swedish health care region are referred to the University
Hospital of Lund, including all stages of breast cancer. Patients are
referred to the hospital and randomly allocated to any of the oncol-
ogists working with breast cancer. This material therefore consists
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region between 1978 and 1997 (excluding 1980 and 1981).
Relatively fewer very old patients are referred for radiation treat-
ment. Lund is the only hospital giving radiation treatment in the
region (excluding Malmö city). The main reason for not referring
patients for radiation treatment is due to randomized trials, where
treatment arms are excluding radiation treatment in stage 1 and
stage 2 patients. The present study is, therefore, based on a random
sample of approximately 11% of all breast cancer patients from
the south Swedish health care region during this period.
From November 1978 to spring of 1997 (excluding 1980 and
1981) all breast cancer patients seen by one of us (HO) were inter-
viewed. This study has been approved by the Ethical Committee
for Medical Research at the University of Lund. Information
obtained included age, previous cancers, menopausal status, age at
menopause and use of HRT, as well as physical characteristics
such as height and weight. Information regarding date at diag-
nosis, and T-, N- and M-stage was obtained from the South
Swedish Tumour Registry, clinical information and the cancer care
programme. T- and N-staging was based on pathological post-
surgical information. Women with previous breast cancers were
excluded from this study as a previous breast cancer may have
influenced the use of oestrogen compounds. Until spring 1997, a
total of 984 breast cancer patients who were 45 years or older at
diagnosis and without previous breast cancers had been inter-
viewed. Eight hundred and forty-nine patients had never used HRT
and 135 patients had ever used HRT prior to their breast cancer
diagnosis. One hundred and thirteen women had ever used
oestrogen replacement therapy, while 30 women had ever used a
combined oestrogen–progestagen replacement therapy. Some
women had used both oestrogen alone and a combination of
oestrogen and progesterone. As there were too few women on the
combined regimen the groups have been combined into an HRT
group. The breast cancers were more often detected due to symp-
toms than screening. See Table 1 for characteristics of the women
included.
In order to obtain time of survival from diagnosis, the 984 breast
cancer patients were matched against the population census
registry 1 March 1997, from which date of death was obtained.
The follow-up was 100% complete.
ER and PR contents were measured with two different tech-
niques: ER content was measured with isoelectric focusing in
polysaccharide gels and enzyme immuno-assay, and PR content
with enzyme immuno-assay and a dextran-coated charcoal method
with Scatchard analysis (Fernö et al, 1989, 1983, 1986) enzyme
immuno-assay was performed according to kit instructions (Abbot
Laboratories, Diagnostic Division, Chicago, IL, USA). Samples
with receptor content values of ³ 10 (isoelectric focusing and
dextran-coated charcoal method) or ³ 25 (enzyme immuno-assay)
fmol mg–1 protein were classified as ER- or PR-positive, and
samples with values below these levels as ER- or PR-negative
(Sigurdsson et al, 1990). As different methods have been used for
analyses of receptor content, an adjustment factor was applied, and
ER and PR contents ³ 25 were considered positive.
Statistics
For univariate analyses of survival time in relation to HRT use, the
Kaplan–Meier method and the log-rank test were used. For
univariate analysis on receptor status and mode of diagnosis in
relation to HRT the c2 test was used. For the multivariate models
also taking T-, N-, M-stage and age of diagnosis into account, a
Cox regression model was used. The assumption of a proportional
hazard was approximately valid. These calculations were done
by the SPSS statistical program. Test for linear trend between
HRT-use and T-stage was also done.
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Table 1 Overall survival studied among a random consecutive sample of breast cancer patients from southern Sweden,
diagnosed between 1978 and 1997
All HRT users Never-users
(n = 984) (n = 135) (n = 849)
Mean (Range) Mean (range) Mean (Range)
Age at diagnosis 59.9 (45–87) 60.3 (45–83) 59.8 (45–87)
Days of survival 2875 (0–6687) 2953 (86–6415) 2862 (0–6687)
Age at menopause 49.7 (30–62) 49.5 (30–57) 49.7 (30–62)
HRT (months) 60.3 (1–240) 0
n (%) n (%) n (%)
Detected by
Screening 121 (12.3) 24 (17.8) 97 (11.4)
Symptoms 590 (60.0) 100 (74.1) 490 (57.7)
Missing 273 (27.7) 11 (8.1) 262 (30.9)
Oestrogen receptor
Positive 486 (49.4) 70 (51.9) 416 (59.0)
Negative 244 (24.8) 27 (20.0) 217 (25.6)
Missing 254 (25.8) 38 (28.1) 216 (25.4)
Progesterone receptor
Positive 360 (36.6) 54 (40.0) 306 (36.0)
Negative 299 (30.4) 36 (26.7) 263 (31.0)
Missing 325 (33.0) 45 (33.3) 280 (33.0)
Characteristics of the women included in this study are shown. There were no significant differences between HRT users and
never-users when comparing mode of diagnosis (P = 0.44), oestrogen receptor status (P = 0.21) and progesterone receptor status
(P = 0.27).RESULTS
Four hundred and thirty out of the 984 patients included in this
study had died. Among the 849 non-users, 395 women had died
(46.5%), and among the 135 HRT-users 35 had died (25.9 %). No
significant correlations were seen between mode of diagnosis and
HRT use, or height and weight and HRT-use.
In a univariate model including all 984 women, 135 ever HRT
users and 849 never-users, HRT use was significantly positively
associated with a longer survival time (P = 0.0004) (Figure 1).
After adjustment for year and age of diagnosis, the relative risk
(RR) of dying for HRT users was 0.74 (95% confidence interval
(CI) 0.62–0.87; P = 0.0005). A Cox regression model (n = 949)
also taking T-, N-, M-stage, year and age at diagnosis into account,
showed that HRT users had a significantly improved overall
survival after diagnosis, RR of dying 0.78 (95% CI 0.65–0.93;
P = 0.006). T-, N-, M-stage and age at diagnosis were all signifi-
cantly associated with time of survival (P < 0.0001) respectively.
In order to be able to calculate 95% CIs we divided T-stage into
low and high T-stage, defining T-stage 1 as low and T-stages 2–4 as
high. For N-stage, we defined N-stage 0 as low and N-stages 1–3
as high (Table 2). When including height and weight into the
model, these two factors were not significantly associated with
overall survival and did not essentially alter the results.
For 5 or more years of HRT use (n = 892) the RR of dying was
0.77 (95% CI 0.56–1.08) and for fewer than 5 years of HRT use
(n = 935) RR 0.78 (95% CI 0.63–0.96) compared with never-users,
after adjustment for high T-, N-, M-stage and age at
diagnosis. Duration of HRT use was known in 129 of the 135
women who were ever-users.
As breast cancer would be the main cause of death in women
between 45 and 60 years of age, we narrowed the age-span to
women with age of diagnosis between these ages. In a univariate
model including 538 women, of whom 74 were ever-users and 464
never-users, HRT use was significantly positively associated with a
longer survival time (P = 0.0177) (Figure 2). Using the regression
model also taking T-, N-, M-stage, year of diagnosis and age at
diagnosis into account (n = 520), showed that HRT users had a
trend toward improved overall survival after diagnosis RR of dying
0.77 (95% CI 0.59–1.01; P = 0.0611). T-stage (P = 0.0028), N-
stage (P < 0.0001) and M-stage (P < 0.0001) were significantly
associated with overall survival, but not with either year of diag-
nosis (P = 0.90) or age at diagnosis (P = 0.34). In order to be able
to calculate 95% CIs we divided T-, N-, M-stage into low and high
Overall survival after HRT in breast cancer patients 1455
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Figure 1 Overall survival time in relation to hormone replacement therapy
(HRT) use in breast cancer patients diagnosed at age 45 years or older.
Women who had ever used HRT before diagnosis had a significantly higher
overall survival (log-rank P = 0.0004, Kaplan–Meier)
Table 2 Overall survival studied among a random consecutive sample of
breast cancer patients from southern Sweden, diagnosed between 1978 and
1997 and treated at Lund University Hospital
Variable B s.e.m. Wald P-value R OR (95% CI)
HRT –0.25 0.09 7.47 0.006 –0.03 0.78 (0.65–0.93)
T-stage
(high/low) 0.30 0.06 27.31 0.000 0.07 1.34 (1.20–1.50)
N-stage
(high/low) 0.37 0.06 38.36 0.000 0.07 1.45 (1.29–1.62)
M-stage
(high/low) 0.51 0.11 23.92 0.000 0.06 1.66 (1.34–2.06)
Cox regression model including 949 of the 984 women with breast cancer
diagnosis at age 45 years or older, analysing the relationship between HRT
use and time of survival after breast cancer diagnosis; 410 women had died.
HRT use was significantly associated with lower risk of dying (P = 0.006)
after adjustment for age and year of diagnosis.
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Figure 2 Overall survival time in relation to hormone replacement therapy
(HRT) use in breast cancer patients diagnosed between 45 and 60 years of
age. Women who had ever used HRT before diagnosis had a significantly
higher overall survival (log-rank P = 0.018, Kaplan–Meier)
Table 3 Overall survival studied among a random consecutive sample of
breast cancer patients from Southern Sweden, diagnosed between 1978 and
1997 and treated at Lund University Hospital
Variable B s.e.m. Wald P-value R OR (95% CI)
HRT –0.26 0.14 3.49 0.061 –0.03 0.77 (0.59–1.01)
T-stage
(high/low) 0.25 0.08 8.91 0.000 0.06 1.28 (1.09–1.51)
N-stage
(high/low) 0.57 0.09 37.49 0.000 0.13 1.77 (1.47–2.12)
M-stage
(high/low) 0.77 0.18 19.02 0.000 0.09 2.16 (1.53–3.05)
Cox regression model including 520 of the 538 women with breast cancer
diagnosis at age 45–60 years, analysing the relationship between HRT use
and time of survival after breast cancer diagnosis. 184 women had died. HRT
use was associated with lower risk of dying (P=0.061), after adjustment for
age and year of diagnosis.as described above (Table 3). When entering height and weight
into the model, a short height was significantly associated with
shorter overall survival (P = 0.02) and so was a heavy weight
(P = 0.002), while the results from the other factors remained
essentially the same. There was no significant difference in time of
survival depending on whether a woman had used HRT for 5 years
or more, versus fewer than 5 years after adjustment for high T-,
N-, M-stage and age at diagnosis.
Comparing the influence of HRT on T-stage and N-stage among
women with breast cancer diagnosed at age 45 years or older
showed that HRT was associated with a lower T-stage, i.e. smaller
tumours, test for linear trend (P = 0.007). In spite of a lower
T-stage among HRT users, no difference concerning lymph node
positivity at the time of diagnosis was found between ever-users
and never-users (Table 4).
ER status was successfully analysed in 730 breast tumours; 244
women had ER-negative tumours and 486 women had ER-positive
tumours. In a Cox regression model it was shown that ER posi-
tivity was associated with less risk of dying (RR 0.76; 95% CI
0.68–0.85; P < 0.0001) and so was HRT use (RR 0.75; 95%
CI 0.62–0.92; P = 0.005), after adjustment for year of diagnosis.
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Table 4 Comparing T- and N-stage in women with their breast cancer
detected at age 45 years or above in a random consecutive sample of breast
cancer patients from southern Sweden, diagnosed between 1978 and 1997
and treated at Lund University Hospital
Never-users HRT Percent
users HRT users
T-stage
1 357 73 17.0
2 355 48 11.9
3 72 8 10.0
4 54 5 8.5
N-stage
Negative 318 55 14.7
Positive 512 77 13.1
Women who ever used HRT were more likely to have their tumour detected
at an earlier T-stage, test for linear trend (P = 0.0068), whereas no difference
was found between N-stages. N-stages 1–3 were analysed as lymph node
positive as too few women had stage 2 and 3 for meaningful comparisons.
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Figure 3 Overall survival time in relation to hormone replacement therapy
(HRT) use in oestrogen receptor-positive breast cancer patients, aged 45
years and older. HRT use was borderline significantly associated with longer
survival (log-rank P = 0.050, Kaplan–Meier)
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
C
u
m
u
l
a
t
i
v
e
 
s
u
r
v
i
v
a
l
0 5 10 15 20
Follow-up time (years)
Yes – censored
No
No – censored
Yes
HRT use
Figure 4 Overall survival time in relation to hormone replacement therapy
(HRT) use in oestrogen receptor-negative breast cancer patients, aged 45
years and older. HRT use was non-significantly associated with longer
survival (log-rank P = 0.061, Kaplan–Meier)
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Figure 5 Overall survival time in relation to hormone replacement therapy
(HRT) use in progesterone receptor-positive breast cancer patients, aged 45
years and older. HRT use was significantly associated with longer survival
(log-rank P = 0.037, Kaplan–Meier)
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Figure 6 Overall survival time in relation to hormone replacement therapy
(HRT) use in progesterone receptor-negative breast cancer patients, aged 45
years and older. HRT use was significantly associated with longer survival
(log-rank P = 0.035, Kaplan–Meier)PR status was successfully analysed in 659 breast tumours; 299
women had PR-negative tumours and 360 women had PR-positive
tumours. PR positivity was associated with less risk of dying
(RR 0.81; 95% CI 0.72–0.91; P = 0.0004) and so was HRT use
(RR 0.71; 95% CI 0.57–0.89; P = 0.003), after adjustment for
year of diagnosis. When analysing ER-positive and ER-negative
tumours separately among women aged 45 years and older at diag-
nosis, HRT use was borderline significantly associated with longer
overall survival in women with ER-positive tumours (log-rank
P = 0.050) and also non-significantly associated with longer
overall survival (log-rank P = 0.061) in women with ER-negative
tumours (Figures 3 and 4). Among women with PR-positive breast
tumours, HRT use was significantly associated with longer
survival (log-rank P = 0.037), and also in PR-negative breast
cancer patients, HRT use was significantly associated with longer
survival (log-rank P = 0.035) (Figure 5 and 6).
Comparing overall survival between ever-users and never-
users in a regression model and also taking screening versus
symptomatic detection into account, 705 women were eligible for
analysis, both HRT use and detection by screening were indepen-
dently significantly associated with longer overall survival
(P = 0.039 and P = 0.002 respectively).
DISCUSSION
The main finding in this study was that the overall survival among
breast cancer patients was significantly longer in women who had
ever been treated with HRT before diagnosis compared with
women who never used HRT. This was true both for women with
ER-positive and ER-negative as well as PR-positive and PR-nega-
tive tumours. Women whose tumours were detected by screening
also had significantly longer overall survival compared with
women whose cancers were symptomatic at diagnosis. When
adjusted for mode of detection, T-, N- and M-stage, age at
diagnosis and tumour receptor status, ever-use of HRT was still
significantly associated with longer overall survival after breast
cancer diagnosis. No separate analyses were done on specific
causes of deaths.
Others have found that prior post-menopausal oestrogen
replacement therapy does not compromise breast cancer survival
(Bergkvist et al, 1989; Strickland et al, 1992). In the Nurses Health
Study it was shown that overall mortality among women using
HRT was lower than among non-users, but that the survival benefit
diminished with longer duration of use mainly due to increased
risk of dying from breast cancer, and was lower for women with a
low risk of coronary disease (Grodstein et al, 1997). Among
women using HRT for more than 10 years, the risk of dying of
breast cancer was increased by 43%. In addition, they found no
apparent overall survival benefit from past hormone use, which is
in contrast with our finding of a longer overall survival among
women who had ever used HRT prior to their breast cancer diag-
nosis irrespective of duration. We did not find any significant
differences in overall survival between women using HRT for 5
years or more versus a shorter period of use.
We found that HRT users were more likely than never-users to
have their tumours detected at a lower T-stage, whereas there was
no difference in lymph node spread. In contrast with our finding,
Jones et al (1994) found that the percentage of all HRT users with
involved lymph nodes (23%) were significantly lower than the
percentage of non-users (44%) among 258 non-users and 39 HRT
users in Australia. Another study from a Swedish population
reported that HRT users had non-significantly smaller tumours and
also a non-significantly lower risk of lymph node involvement
(Magnusson et al, 1996). Although there were no significant
differences between HRT users and never-users in the present
study when comparing mode of diagnosis, a significantly larger
proportion of never-users had missing information on mode of
diagnosis. We have no clear reason for this discrepancy, but one
hypothesis could be that HRT users may provide more accurate
information about how their tumours were detected. However, we
have no reason to believe that the true mode of detection in women
with missing information should be distributed unevenly between
HRT users and never-users. It is possible that HRT users are more
concerned about their health, and that this attitude would be
reflected in more careful overall health surveillance leading to
better survival. This matter has been previously discussed by other
groups (reviewed by Schairer et al, 1994). Further insight into this
matter would require a differently designed study.
In our study, women with breast cancer diagnosed at ages 45–60
years, where breast cancer is the main cause of death, we found the
survival benefit from HRT use to be 22.5%. This approaches the
one seen with mammography screening where a 29% death reduc-
tion has been seen among women aged 50–69 years (Nyström
et al, 1993).
We consider it an advantage that we interviewed women
regarding their hormonal use instead of relying on prescriptions,
since there is no guarantee that a woman actually uses the HRT
during the intended period, or indeed at all. One study examining
the consistency between oral contraceptive use reported by
patients and the information in medical records, found that patient
information on total duration, numbers of episodes of use, and
time since first and last use agreed reasonably well with medical
records, while oral contraceptive brand names and duration of use
of a specific brand showed less consistency between medical
record and patient information (Nischan et al, 1992). Persson et al
(1997) found several differences among women who had been
prescribed HRT in the choice of complying with the prescription.
They found that women denying intake or using HRT short-term
(1–72 months) had higher parity, earlier age at first birth and a
lower prevalence of hysterectomy or oophorectomy than those
complying or exposed long-term. A high level of education was
associated with compliance and long-term use, heavy physical
exercise and high fibre intake were associated with compliance. In
this study we have not distinguished between specific brand names
and have asked the women themselves of duration of their HRT
instead of using prescription records.
One question raised has been whether HRT users are healthier
than non-users prior to use (Yuen et al, 1993; Matthews et al,
1996). One study on HRT compliance (Persson et al, 1997)
reported that there were several connections between known risk
factors for breast cancer and the use of HRT. We found no signifi-
cant correlation between height or weight and HRT use. However,
it is likely that women who suffer most from oestrogen deficiency
also seek help for their symptoms. Lean women are at less risk for
developing post-menopausal breast cancer than heavier women
(Hunter and Willet, 1993), and they are also more likely to be
oestrogen-deficient than heavier women as oestrogen is formed in
fatty tissue. We found that leaner and taller women had signifi-
cantly longer overall survival than shorter and heavier women in
the age-group of 45–60 years at breast cancer diagnosis, after
adjustment for HRT, T-, N-, M-stage and age at diagnosis. This
effect from height and weight was not significant when the whole
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that women with distal forearm fractures had a better survival than
expected, mainly due to lower rates of death from malignant
tumours and circulatory disease including myocardial infarction
(Olsson and Hägglund, 1992). As bone fractures could be a sign of
osteoporosis and thus low oestrogen levels, this group of women
may also constitute a target group for HRT prescriptions. Forearm
fractures may also reflect a physically active life, and the latter
study (Olsson and Hägglund, 1992) showed that at least this group
of women already had a better survival rate than expected,
including less risk of circulatory disease. Therefore one should be
cautious when interpreting the effect with an overall longer
survival among HRT users. Is the benefit caused by HRT itself or
would the group of women prescribed HRT have survival longer
even without it?
We found a longer overall survival after breast cancer diagnosis
among ever-users of HRT regardless of their tumour receptor
status. However, there may be subgroups of women who do not
benefit from HRT use which we have been unable to detect in our
study. Some of the ever-users may never have developed their
breast cancer if they had not used HRT. For a total evaluation of
the risk and benefits of HRT a cohort must be followed for a
life-time.
In conclusion, we have found that ever-use of HRT before breast
cancer diagnosis is significantly associated with longer survival
after diagnosis independent of tumour stage, ER and PR status and
mode of diagnosis.
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